• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在患有pp65抗原血症的肾移植受者中,人巨细胞病毒特异性CD8(+) T淋巴细胞表现出干扰素-γ分泌受损。

Human cytomegalovirus specific CD8(+) T lymphocytes display interferon-gamma secretion impairment in kidney transplant recipients with pp65 antigenemia.

作者信息

Yang R, Xia T, Xu G, Li Z, Ying Z, Xu X

机构信息

Department of Clinical Laboratory, Peking University First Hospital, Beijing, China.

出版信息

Transplant Proc. 2008 Dec;40(10):3500-4. doi: 10.1016/j.transproceed.2008.03.176.

DOI:10.1016/j.transproceed.2008.03.176
PMID:19100424
Abstract

Our study sought to investigate the immune response of cytotoxic T lymphocytes to human cytomegalovirus (HCMV) in kidney transplant recipients with virus reactivation. Nine kidney transplant recipients with serum HCMV immunoglobulin G and HLA-A 0201 genotype displayed HCMV pp65 antigenemia and were compared with 29 control recipients who were free of antigenemia. The frequency of total HCMV-specific cytotoxic T cells was determined using HLA-A2-NLVPMVATV-pentamer staining. The frequency of HCMV specific interferon (INF)-gamma secreting CD8(+) T cells was determined using intracellular INF-gamma staining after NLVPMVATV pulsing in vitro. The proportion of IFN-gamma secreting pentamer-stained CD8(+) T cells was calculated, representing the capacity for INF-gamma secretion among HCMV-specific CD8(+) T cells. We observed that the frequency of HCMV-specific pentamer-stained CD8(+) T cells and HCMV-specific IFN-gamma secreting CD8(+) T cells both remained unchanged, yet the proportion of IFN-gamma secreting CD8(+) T cells showed a significant difference between the 2 groups (39.2% +/- 17.2% vs 20.0% +/- 13.3% respectively; P = .004), reflecting impaired IFN-gamma secreting capacity of HCMV-specific CD8(+) T cells among kidney transplant recipients displaying antigenemia, which may be a crucial reason for HCMV reactivation in immunosuppressed patients.

摘要

我们的研究旨在调查肾移植受者病毒再激活时细胞毒性T淋巴细胞对人巨细胞病毒(HCMV)的免疫反应。9名血清HCMV免疫球蛋白G和HLA - A 0201基因型的肾移植受者出现HCMV pp65抗原血症,并与29名无抗原血症的对照受者进行比较。使用HLA - A2 - NLVPMVATV - 五聚体染色法测定总HCMV特异性细胞毒性T细胞的频率。在体外经NLVPMVATV刺激后,使用细胞内γ干扰素(INF - γ)染色法测定HCMV特异性分泌INF - γ的CD8(+) T细胞的频率。计算分泌INF - γ的五聚体染色CD8(+) T细胞的比例,代表HCMV特异性CD8(+) T细胞中INF - γ的分泌能力。我们观察到,HCMV特异性五聚体染色CD8(+) T细胞和HCMV特异性分泌INF - γ的CD8(+) T细胞的频率均保持不变,但两组之间分泌INF - γ的CD8(+) T细胞比例存在显著差异(分别为39.2%±17.2%和20.0%±13.3%;P = .004),这反映出在出现抗原血症的肾移植受者中,HCMV特异性CD8(+) T细胞分泌INF - γ的能力受损,这可能是免疫抑制患者中HCMV再激活的关键原因。

相似文献

1
Human cytomegalovirus specific CD8(+) T lymphocytes display interferon-gamma secretion impairment in kidney transplant recipients with pp65 antigenemia.在患有pp65抗原血症的肾移植受者中,人巨细胞病毒特异性CD8(+) T淋巴细胞表现出干扰素-γ分泌受损。
Transplant Proc. 2008 Dec;40(10):3500-4. doi: 10.1016/j.transproceed.2008.03.176.
2
Detection of human cytomegalovirus-specific T lymphocytes in human blood: comparison of two methods.人血液中人类巨细胞病毒特异性T淋巴细胞的检测:两种方法的比较
Cytotherapy. 2008;10(8):834-41. doi: 10.1080/14653240802474315.
3
Evaluation of human cytomegalovirus-specific CD8+ T-cells in allogeneic haematopoietic stem cell transplant recipients using pentamer and interferon-γ-enzyme-linked immunospot assays.采用五聚体和干扰素-γ-酶联免疫斑点法评估异基因造血干细胞移植受者的人巨细胞病毒特异性 CD8+T 细胞。
J Clin Virol. 2013 Oct;58(2):427-31. doi: 10.1016/j.jcv.2013.07.006. Epub 2013 Jul 30.
4
Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.成人异基因造血干细胞移植受者中人类巨细胞病毒特异性CD4+和CD8+ T细胞重建及病毒感染的免疫控制
Haematologica. 2008 Feb;93(2):248-56. doi: 10.3324/haematol.11912.
5
Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.监测异基因干细胞移植后巨细胞病毒IE-1和pp65特异性CD4+及CD8+ T细胞反应,可能会识别出有巨细胞病毒反复激活风险的患者。
Cytometry B Clin Cytom. 2008 Jul;74(4):211-20. doi: 10.1002/cyto.b.20420.
6
Monitoring of cytomegalovirus-specific CD8+ T-cell response with major histocompatibility complex pentamers in kidney transplant recipients.
Transplant Proc. 2011 Sep;43(7):2636-40. doi: 10.1016/j.transproceed.2011.05.051.
7
Flow cytometric analysis of virus-specific T lymphocytes: practicability of detection of HCMV-specific T lymphocytes in whole blood in patients after stem cell transplantation.病毒特异性T淋巴细胞的流式细胞术分析:干细胞移植后患者全血中检测人巨细胞病毒特异性T淋巴细胞的实用性
J Immunol Methods. 2006 Apr 20;311(1-2):164-73. doi: 10.1016/j.jim.2006.02.001. Epub 2006 Feb 28.
8
Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host.免疫功能正常和免疫功能低下宿主原发性感染中人类巨细胞病毒特异性CD4+和CD8+ T细胞反应
Clin Immunol. 2009 Jun;131(3):395-403. doi: 10.1016/j.clim.2009.02.002. Epub 2009 Mar 5.
9
Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection.巨细胞病毒特异性 CD8+ T 细胞并非所有处于病毒感染风险的肾移植患者中都能发展。
Transpl Immunol. 2009 Dec;22(1-2):99-104. doi: 10.1016/j.trim.2009.07.003. Epub 2009 Jul 24.
10
Normalizing ELISPOT responses to T-cell counts: a novel approach for quantification of HCMV-specific CD4(+) and CD8(+) T-cell responses in kidney transplant recipients.将ELISPOT反应标准化至T细胞计数:一种用于定量肾移植受者中巨细胞病毒特异性CD4(+)和CD8(+) T细胞反应的新方法。
J Clin Virol. 2014 Sep;61(1):65-73. doi: 10.1016/j.jcv.2014.05.017. Epub 2014 Jun 4.

引用本文的文献

1
Effect of Type of Dialysis on CMV-Specific CD8+ T Cells in Kidney Transplant Candidates.透析类型对肾移植候选者巨细胞病毒特异性 CD8+T 细胞的影响。
Front Immunol. 2019 Jul 19;10:1680. doi: 10.3389/fimmu.2019.01680. eCollection 2019.
2
Monitoring of pathogen-specific T-cell immune reconstitution after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后病原体特异性T细胞免疫重建的监测。
Front Immunol. 2013 Sep 17;4:276. doi: 10.3389/fimmu.2013.00276.